NuVasive, Inc.

NasdaqGS:NUVA Stock Report

Market Cap: US$2.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NuVasive Valuation

Is NUVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NUVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$75.63
Fair Value
47.4% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: NUVA ($39.75) is trading below our estimate of fair value ($75.63)

Significantly Below Fair Value: NUVA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NUVA?

Key metric: As NUVA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NUVA. This is calculated by dividing NUVA's market cap by their current earnings.
What is NUVA's PE Ratio?
PE Ratio73.3x
EarningsUS$28.45m
Market CapUS$2.08b

Price to Earnings Ratio vs Peers

How does NUVA's PE Ratio compare to its peers?

The above table shows the PE ratio for NUVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21x
CNMD CONMED
15.8x7.05%US$1.8b
LMAT LeMaitre Vascular
41.3x9.52%US$1.8b
LIVN LivaNova
n/a67.14%US$2.4b
INMD InMode
5.8x-10.38%US$980.7m
NUVA NuVasive
73.3x46.22%US$2.1b

Price-To-Earnings vs Peers: NUVA is expensive based on its Price-To-Earnings Ratio (73.3x) compared to the peer average (39.2x).

Price to Earnings Ratio vs Industry

How does NUVA's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
PAVM PAVmed
0.7x-111.94%US$21.25m
MHUA Meihua International Medical Technologies
1.3xn/aUS$9.82m
MOTS Motus GI Holdings
n/an/aUS$7.00
No more companies available in this PE range
NUVA 73.3xIndustry Avg. 32.0xNo. of Companies7PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NUVA is expensive based on its Price-To-Earnings Ratio (73.3x) compared to the US Medical Equipment industry average (36.1x).

Price to Earnings Ratio vs Fair Ratio

What is NUVA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NUVA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio73.3x
Fair PE Ratio47.9x

Price-To-Earnings vs Fair Ratio: NUVA is expensive based on its Price-To-Earnings Ratio (73.3x) compared to the estimated Fair Price-To-Earnings Ratio (47.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NUVA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
May ’26n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Apr ’26n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Mar ’26n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Feb ’26n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Jan ’26n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Dec ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Nov ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Oct ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Sep ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Aug ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Jul ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Jun ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
May ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Apr ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Mar ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Feb ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Jan ’25n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Dec ’24n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Nov ’24n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Oct ’24n/a
US$49.00
0%
11.36%US$58.00US$44.00n/a8
Sep ’24US$39.75
US$49.00
+23.27%
11.36%US$58.00US$44.00n/a8
Aug ’24US$40.84
US$49.06
+20.13%
11.77%US$58.00US$40.00n/a12
Jul ’24US$41.59
US$48.81
+17.36%
11.78%US$58.00US$40.00n/a12
Jun ’24US$38.55
US$48.81
+26.61%
11.78%US$58.00US$40.00n/a12
May ’24US$42.97
US$49.35
+14.85%
9.45%US$58.00US$44.00n/a12
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
US$49.00
Fair Value
18.9% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/02 09:24
End of Day Share Price 2023/08/31 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NuVasive, Inc. is covered by 37 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays